Current methodologies for detecting sensitization to HLA antigens

Current Opinion in Organ Transplantation

Volumn 16, Issue 4, 2011, Pages 398-403

  Cecka, J Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibodies; HLA; kidney transplant; sensitization; solid phase

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN G; PANEL REACTIVE ANTIBODY;

B LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; KIDNEY DONOR; KIDNEY GRAFT; LYMPHOCYTE; REVIEW; SENSITIZATION; SOLID;

ANTIBODY SPECIFICITY; COMPLEMENT FIXATION TESTS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DESENSITIZATION, IMMUNOLOGIC; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MONITORING, IMMUNOLOGIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SOLID PHASE EXTRACTION;

EID: 80051802723     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328348980a     Document Type: Review

References (40)

1. Duquesnoy RJ, Marrari M. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. Tissue Antigens 2009; 74:117-133.
2. Marrari M, Duquesnoy RJ. Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens. Tissue Antigens 2009; 74:134-146.
3. Duquesnoy RJ, Marrari M. HLAMatchmaker-based definition of structural human leukocyte antigen epitopes detected by alloantibodies. Curr Opin Organ Transplant 2009; 14:403-409; Review.
4. Tambur AR, Leventhal JR, Friedewald JJ, Ramon DS. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90:1117-1124. This study reports that a high percentage of patients with anti-DQ antibodies made antibodies against the polymorphic alpha or beta chains of HLA-DQ antigens. These complex antibodies are often a challenge in the virtual crossmatch.
5. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplantation 2010; 10:582-589. This study used a combination of tests to show that the risk of antibody-mediated damage after transplant increased with the level of DSA present before transplantation. The data suggest that setting very low thresholds for DSA may prevent many transplants that would have good outcomes.
6. Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: A prospective study in 233 renal transplantations. Transpl Int 2011; 24:560-569.
7. Eng HS, Bennett G, Chang SH, et al. Donor HLA specific antibodies predict development and define prognosis in transplant glomerulopathy. Hum Immunol 2011; 72:386-391.
8. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86:820-825.
9. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10:2033-2042.
10. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols. Am J Transplant 2010; 10:449-457. The author points out that combinations of paired donation and desensitization -avoiding and/or overcoming DSA -provide the best options for patients with incompatible living donors.
11. Veale J, Hil G. National Kidney Registry: 213 transplants in 3 years. In Cecka JM, Terasaki PI, editors. Clinical transplants 2010. Terasaki Foundation Laboratory: Los Angeles; 2011. pp. 333-344.
12. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS. Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2010; 11:719-724. A study of the UNOS data 6 months following the change to calculated PRA and virtual cross-matching showed that virtual cross-matches based on solid-phase tests were very accurate and resulted in more transplants for broadly sensitized patients. Despite some remaining limitations to the solid-phase tests, they have proven beneficial for many sensitized patients.
13. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68-74. This multicenter study reports that nearly 60% of patients with new-onset graft dysfunction 5 years after transplantation had DSA or C4d in biopsies and that these patients' subsequent graft survival was significantly worse than those without evidence of antibody-mediated injury. New DSA long after transplant was a major cause of late graft failure.
14. Süsal C, Ovens J, Mahmoud K, et al. No Association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive luminex single-antigen testing: A collaborative transplant study report. Transplantation 2011; 91:883-887. A registry study of more than 3000 recipients with antibody testing performed centrally suggests DSA detected only by the single antigen bead test do not increase graft losses during the first 3 years and should not be used to exclude patients from transplantation.
15. Doxiadis II, Roelen D, Claas FH. Mature wines are better: CDC as the leading method to define highly sensitized patients. Curr OpinOrgan Transplant 2010 [Epub ahead of print].
16. Ishida H, Hirai T, Kohei N, et al. Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transpl Int 2011; 24:150-157.
17. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398-1406. These authors report that even very low levels of DSA detected only in historical but not current serum samples can affect transplant outcome.
18. Tait BD, Hudson F, Brewin G, et al. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens 2010; 76:87-95. This is a very comprehensive literature review highlighting the development of solid-phase tests for HLA antibody and outlining many of the challenges in interpreting results (66 references including historical).
19. Tait BD, Hudson F, Brewin G, et al. Luminex Technology for HLA antibody detection in organ transplantation [review]. Nephrol 2009; 14:247-254.
20. Bray RA, Gebel HM. Strategies for human leukocyte antigen antibody detection [review]. Curr Opin Organ Transplant 2009; 14:392-397.
21. Gebel HM, Bray RA. The evolution and clinical impact of human leukocyte antigen technology [review]. Curr Opin Organ Transplant 2010; 19:598-602.
22. Leffell MS, Zachary AA. Antiallograft antibodies: Relevance, detection and monitoring [review]. Curr Opin Organ Transplant 2010; 15:2-7.
23. Zachary AA, Leffell MS. Barriers to successful transplantation of the sensitized patient [review]. Expert Rev Clin Immunol 2010; 6:449-460.
24. Billen EV, Christiaans MH, Doxiadis II, et al. HLA-DP antibodies before and after renal transplantation. Tissue Antigens 2010; 75:278-285.
25. Duquesnoy RJ, Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transplant Immunol 2011; 24:164-171.
26. Stastny P, Salvador IM, Lavingia B. Evaluation of the highly sensitized transplant recipient. Pediatr Nephrol 2011 [Epub ahead of print]. doi: 10.1007/s00467-010-1732-6.
27. El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70:844-853.
28. Pereira S, Perkins S, Lee JH, et al. Donor-specific antibody against denatured HLA-A1: Clinically nonsignificant? Hum Immunol 2011; 72:492-498.
29. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: Characteristics and resolution. Hum Immunol 2009; 70:496-501; erratum in Hum Immunol 2009; 70:872-876.
30. Taylor CJ, Kosmopoliaptis V, Sharples LD, et al. Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 2010; 89:185-193. These results suggest that careful monitoring of patients for anti-HLA antibodies and for potential sensitizing events before transplantation provides the confidence to forgo final crossmatches for unsensitized patients.
31. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 2011; 91:527-535. DSA detected only by solid-phase tests and not by a flow cytometry crossmatch did not affect short-term graft outcomes (1 year).
32. Morris GP, Phelan DL, Jendrisak MD, Mohanakumar T. Virtual crossmatch by identification of donor-specific antihuman leukocyte antigen antibodies by solid-phase immunoassay: A 30-month analysis in living donor kidney transplantation. Hum Immunol 2010; 71:268-273. The use of multiple tests to assess the relevance of DSA is an important strategy. The authors use 'limited exclusion of donors with a high likelihood of positive crossmatch' rather than excluding those with any possibility of a positive crossmatch.
33. Batal I, Zeevi A, Lunz JG 3rd, et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010; 134:1534-1540. This study used proficiency test samples which may be selected to include strong antibodies and may not reflect the spectrum of patient samples that could be encountered.
34. Verghese PS, Smith JM, McDonald RA, et al. Impaired graft survival in pediatric renal transplant recipients with donor-specific antibodies detected by solid-phase assays. Pediatr Transplant 2010; 14:730-734.
35. Riethmüller S, Ferrari-Lacraz S, Müller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibodymediated rejection in kidney transplantation. Transplantation 2010; 90: 160-167.
36. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 2009; 9:1826-1834.
37. Lobashevsky A, Rosner K, Goggins W, Higgins N. Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol 2010; 23:81-85.
38. Hönger G, Wahrmann M, Amico P, et al. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89:1471-1475. These authors had developed this test and showed correlation with C4d deposition in biopsies, but that relationship did not hold true for weaker antibodies.
39. Mizutani K, Gotoh M. C4d binding correlated with strong HLA antibodies involved in graft failure. Transplant Proc 2010; 42:4021-4025. This study raises some question about the complement fixation tests. Do they just eliminate detection of weaker antibodies?
40. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91:342-347. Measuring functionality of DSA is an approach that is generating interest, but needs study. This test has been made commercially available.